Botox-maker AbbVie lifts profit guidance

Investors have been focused on how companies are navigating existing tariffs and the potential for new levies to be imposed on pharmaceutical imports to the US

Some analysts see the company as “a relatively safe haven” compared to its peers.

Botox-maker AbbVie raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments.

The drugmaker said it now sees 2025 adjusted earnings in the range of $12.09 to $12.29 a share, up from a prior forecast of $11.99 to $12.19, including impacts from ongoing research and development.